AiRWA YYAI
AiRWA FY 2026: revenue $25.8M, up 101%; diluted EPS −$752.73
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001493152-26-043608
Key figures from this report
These are the numbers AiRWA reported for the year ended Apr 30, 2026, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$25.8M+101% from $12.8M in FY 202510-K income statement, on EDGAR
- Net income−$17.6M−603% from $3.5M in FY 202510-K income statement, on EDGAR
- Diluted EPS−$752.73−107% from $10,842.51 in FY 202510-K income statement, on EDGAR
- Cash and cash equivalents$12.8M+23245% from $55K in FY 202510-K balance sheet, on EDGAR
- Cash from operations−$20.9MAgainst −$379K in FY 202510-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 7370 and related industry codes: the same peer list as the financial tables.
- Nixxy NIXX public float $41M, Jun 30, 2025
- BioScience Health Innovations BHIC public float $44M, Jun 30, 2025
- Moatable MTBLY
- Healthcare Triangle HCTI public float $41M, Jun 30, 2025
- Veea VEEA public float $40M, Jun 30, 2025